Gold bars to be exempt from tariffs, White House clarifies
RUTHERFORD, N.J./STOCKHOLM - Glucotrack, Inc. (NASDAQ:GCTK), a micro-cap medical device company with a market capitalization of just under $3 million, announced Wednesday that its implantable Continuous Blood Glucose Monitor (CBGM) achieved a Mean Absolute Relative Difference (MARD) of 7.7% in its first human clinical study, meeting all primary and secondary endpoints.
The study, conducted in São Paulo, Brazil between December 13, 2024, and January 31, 2025, involved ten participants with Type 1 or Type 2 diabetes on intensive insulin therapy. Results were presented at the American Diabetes Association’s 85th Scientific Sessions held June 20-23, 2025, in Chicago. According to InvestingPro data, while the company maintains a healthy current ratio of 4.85, indicating strong short-term liquidity, it faces challenges with cash burn as it advances its development programs. InvestingPro analysis reveals 11 additional key insights about Glucotrack’s financial position.
According to the company, the device demonstrated a 99% data capture rate with no procedure or device-related serious adverse events. Analysis using the Diabetes Technology Society Error Grid showed 92% of measurements fell within the green zone, indicating high clinical accuracy compared to reference blood glucose values.
Unlike traditional continuous glucose monitors that measure glucose in interstitial fluid, Glucotrack’s technology measures glucose directly from blood, which the company states eliminates the typical lag time associated with conventional systems.
"With a MARD of 7.7%, which is comparable to leading CGM systems but with direct blood measurement instead of interstitial fluid, we’re advancing our novel technology into further clinical trials," said Paul V. Goode, President and CEO of Glucotrack, in the press release.
The CBGM consists of a sensor lead implanted into the subclavian vein connected to subcutaneous electronics that communicate with a mobile application. The company reports the system is designed for a three-year sensor life with minimal calibration requirements.
Glucotrack plans to initiate a long-term early feasibility study in the third quarter of 2025. The device remains investigational and is limited by U.S. law to investigational use.
In other recent news, Glucotrack, Inc. has announced the completion of a 1-for-60 reverse stock split, which became effective on June 16, 2025. This corporate action reduced the company’s outstanding shares from approximately 34.05 million to about 567,456 shares, with fractional shares rounded up. The reverse split aims to help Glucotrack meet Nasdaq’s $1.00 minimum bid price requirement, as the company faces potential delisting. Additionally, Glucotrack has elected Dr. Victoria E. Carr-Brendel to its Board of Directors, bringing her extensive experience in medical devices to support the company’s strategic goals. The company is also collaborating with OneTwo Analytics to enhance the evaluation of its Continuous Blood Glucose Monitor (CBGM) clinical study data using AI-driven analytics. This partnership is expected to provide clearer insights and improve diabetes management. Glucotrack’s CBGM technology is designed to offer continuous blood glucose monitoring for up to three years without an external wearable component. The company is actively working towards regulatory approval and commercialization of this novel technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.